The Centers for Medicare and Medicaid Services (CMS) launched the voluntary BALANCE model to expand access to GLP-1 medications for weight management and metabolic health improvement for Medicare Part D and state Medicaid enrollees.[1][3] The model will allow state Medicaid agencies to participate beginning in May 2026 and Part D plans beginning in January 2027, with an end date of December 2031.[2][3] CMS will directly negotiate with GLP-1 drug manufacturers for lower net prices, standardized coverage criteria, and evidence-based lifestyle support.[1][2] Prior to the launch of BALANCE, CMS plans a transitional GLP-1 payment demonstration outside of the standard Part D coverage stream beginning in July 2026.1][2] Medicare Part D enrollees who meet the criteria will pay $50 per month for GLP-1 drugs in the demonstration.1][2] The model will be evaluated based on cost, adherence, outcomes, and enrollee experience.1 Applications from manufacturers and interested states and Part D plans are due by January 8, 2026.[2